USFDA Issues Form 483 with Observations After Inspecting Cohance Lifesciences Plant
The US Food and Drug Administration (USFDA) inspected Cohance Lifesciences' formulation plant in Shamshabad, Telangana, from August 27 to September 4, 2026. The inspection resulted in a Form FDA 483 with four observations. Cohance Lifesciences has initiated corrective and preventive actions and plans to respond within the required timeline. The company, formerly Suven Pharmaceuticals, recently reported a consolidated net loss for the quarter ended June 2026, with sales declining compared to the previous year.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 42/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 5 Sept, 06:12 am. Other outlets followed.
- 1businessstandard5 Sept, 06:12 amUSFDA completes inspection of Cohance Lifesciences' formulations unit
- 2businessstandard5 Sept, 09:10 amCohance Lifesciences' Telangana units gets Form FDA 483 with observations from US FDA
Who's involved
Institutions and figures named across source coverage.
Story context
- Category
- Business
- Location
- Telangana, India
- Sources analysed
- 2
- Last analysed
- 5 Sept 2026
- Key entities
- Food and Drug AdministrationTelanganaJSW SteelSteelLakhTonneCroreIndian rupeeBrigade GroupMazagon Dock ShipbuildersForm FDA 483Pharmaceutical industry